All relevant data are within the paper and its Supporting Information files.

Background {#sec006}
==========

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common disorder with a high mortality rate worldwide \[[@pone.0187699.ref001]\]. After a first episode of VTE patients have an elevated risk of a recurrent episode that is as high as 30% to 50% within 10 years in those with unprovoked VTE \[[@pone.0187699.ref002]\]. Major acquired risk factors for VTE include cancer, trauma, surgery, immobilization, pregnancy, use of oral contraceptives and the antiphospholipid syndrome. A family history of VTE increases the risk as well and indicates an important underlying genetic component \[[@pone.0187699.ref003]--[@pone.0187699.ref005]\].

Sequencing-based studies and, to a lesser extent, genome-wide association studies (GWAs), have contributed to the discovery of novel genetic risk factors for VTE \[[@pone.0187699.ref006]--[@pone.0187699.ref014]\] Rare mutations identified by sequencing of candidate genes, i.e. antithrombin, protein C and protein S, are those that convey the highest risk \[[@pone.0187699.ref015]\]. Yet, the currently known genetic risk factors are present in approximately half of the patients with unexplained but familial VTE \[[@pone.0187699.ref016]\], which suggests that other genetic risk factors remain to be identified. The discovery of such genetic causes of VTE may unravel novel disease-causing mechanisms in or outside the coagulation cascade.

The aim of this study was to identify novel genetic risk factors for VTE by whole exome sequencing of 10 individuals from two unrelated Dutch families with an unexplained tendency for VTE, to estimate the prevalence of any candidate variants among patients with familial VTE, and to subsequently validate these in a large population-based case control study. We hypothesized that unexplained familial VTE is caused by the presence of genetic variants located in coding regions of genes with known or unknown roles in hemostasis.

Materials and methods {#sec007}
=====================

Subjects {#sec008}
--------

Two large Dutch families, referred to as Family D and Family K, were selected from the GENES study, which has been described previously \[[@pone.0187699.ref017]\]. In both families, 5 or more individuals had had objectively confirmed VTE, in the absence of known hereditary thrombophilia (antithrombin-, protein C-, and protein S deficiency, factor V Leiden and prothrombin G20210A). All affected individuals from both families had experienced VTE at a relatively young age and some individuals had had DVT at unusual sites (abdomen or arms). The pedigrees are depicted in [Fig 1](#pone.0187699.g001){ref-type="fig"}.

![Pedigree of the families with inherited VTE.\
Half shaded symbols indicate affected individuals. In family D (A), 7 individuals had had objectively confirmed VTE while in family K (B), 5 individuals had had objectively confirmed VTE. Exome data was generated from all individuals surrounded by a red circle. Please notice that although the affected individual 5 from family D was not genetically tested, the genotype of her daughter (individual 11) who also has the same phenotype, is available. Therefore, it can be assumed that all candidate mutations validated in individual 11 are also present in the individual 5. Moreover, none of the individuals from the oldest generation of family K had had an objectively confirmed VTE event. The VTE events for each of the affected individuals from family D are the following: DVT in the leg at age of 46 for individual 59; DVT in the leg at age of 48 for individual 58; DVT in the leg and in the arm, and PE at age of 42, 50, and 52, respectively, for individual 9; DVT in the leg at age of 26 for individual 2; PE at age of 22 for individual 11; DVT in the leg at age of 30 for individual 5, and; DVT in the leg at age of 56 for individual 7. The VTE events for each of the affected individuals from family K are the following: PE at age of 44 for individual 9; DVT in the abdomen at age of 41, 42 and 45 for individual 8; DVT in the leg at age of 53 for individual 5; PE at the age of 43 and 45 for individual 3 and; PE at age of 23 for individual 24.](pone.0187699.g001){#pone.0187699.g001}

In addition to the two families, two sets of patients with familial VTE, as well as a population-based case-control study of VTE were included in this study. The patients with familial VTE comprised of 36 unrelated cases with familial VTE from the GENES study \[[@pone.0187699.ref017]\], and 434 cases with VTE from 201 families from the GIFT study, which included affected sibs with thrombosis before the age of 45, in the absence of known thrombophilia \[[@pone.0187699.ref018]\]. The population-based MEGA study consisted of 4,291 cases with a first VTE and 4,866 controls \[[@pone.0187699.ref019]\]. Identification of cases and controls has been described in detail previously \[[@pone.0187699.ref017]--[@pone.0187699.ref019]\]. The GENES study was approved by the Medical Ethics Committee of the Academic Medical Center, Amsterdam, the Netherlands. The GIFT and the MEGA studies were approved by the Medical Ethics Committee of the Leiden University Medical Center, Leiden, the Netherlands. Written informed consent was obtained from all participants.

Whole-exome sequencing {#sec009}
----------------------

### Families {#sec010}

Genomic DNA extracted from whole blood from 5 affected relatives from both families was sent to the Beijing Genomics Institute for whole exome sequencing [Fig 1](#pone.0187699.g001){ref-type="fig"}. The exomes were captured using the Agilent SureSelect Human all Exon (44M) kit and the enriched exome libraries were multiplexed and sequenced on the Illumina HiSeq2000 platform to generate 90-bp paired-end reads per individual with an average sequencing depth above 50x. The exome design covers 44 Mb of human genome corresponding to the exons and flanking intronic regions of \~18,000 genes in the National Center for Biotechnology Information Consensus CDS database (April 2011 release).

The sequencing reads were aligned to the human reference genome sequence NCBI Build 37 (hg19) using the Burrows-Wheeler Aligner (BWA) version (v) 0.6.2. Then, each SAM file resulting from each sample was converted to a BAM file using SAMtools (v0.1.18). Picard tools (v1.78) and GATK tools (v2.2) were used to process the BAM files. Variant calling was performed with all samples simultaneously. Single nucleotide variants/polymorphisms (here globally called as SNPs), as well as insertions and deletions (INDELs), were called by the UnifiedGenotyper walker from GATK tools. After quality score recalibration and removal of low-confidence variants, all SNPs and INDELs were annotated using ANNOVAR (November 2012 release). All steps were performed according to GATK Best Practices recommendations \[[@pone.0187699.ref020]\].

### GIFT study {#sec011}

Genomic DNA extracted from whole blood from 96 unrelated cases with familial VTE from the GIFT study was sent to the The Post-Genomic Platform of the Pitié-Salpêtrière (P3S) for whole exome sequencing. The DNA libraries were performed using TruSeq DNA sample Prep kit (Illumina) and the exomes were captured using the TruSeq Exome Enrichment kit (Illumina). The enriched exome libraries were multiplexed and sequenced on the Illumina HiSeq2000 platform to generate 100-bp paired-end reads per individual with an average sequencing depth above 50x. The exome design covers 62 Mb of human genome corresponding to the exons and UTR regions of 20794 genes.

Illumina\'s CASAVA software v1.8.2 was used to demultiplex samples and convert BCL files to FASTQ format files. Quality controls of the raw data were performed with FastQC (v0.10.1). Reads with poor quality were removed (fastq_illumina_filter-0.1) and low quality bases of the reads were trimmed (sickle v1.200). After these preprocessing steps, sequenced data were aligned to the human genome reference sequence NCBI Build 37 (hg19) using BWA (v0.6.2). Reads in the resulting BAM files were then realigned around INDELs and the base quality score were recalibrated using GATK (v2.4--3). Duplicates and singletons were then removed along with non-well oriented reads using Picard (v1.85) and Samtools (v0.1.18). Variant calling was performed on bases with good quality (Q-score\>20) using the samtools mpileup command. Variants that were present in GIFT and in individuals from families D and K were identified.

Filter strategies {#sec012}
-----------------

To identify the genetic variant responsible for the increased risk for VTE in members from the families D and K, we applied 3 different strategies, summarized in [Fig 2](#pone.0187699.g002){ref-type="fig"}. These strategies were based on: (i) variants within candidate genes (filter strategy 1), (ii) rare variants across the exome (filter strategy 2), (iii) SNPs present in patients with familial VTE and with low frequency (minor allele frequency \< 5%) in the general population (filter strategy 3). All strategies assume that familial VTE is an autosomal dominant disease, and that all affected family members from a certain family share the same genetic risk variant. In addition, variants located in the X chromosome were considered for analysis in filter strategies 1 and 2, as VTE affects both males and females.

![Overview of all filter strategies applied to the whole exome sequencing data derived from the DNA of 10 affected individuals from 2 Dutch families with inherited VTE (5 from each family).\
Three filter strategies were applied to the sequencing data. These strategies were based on: variants within candidate genes (filter strategy 1), rare variants across the exome (filter strategy 2) and, SNPs present in patients with familial VTE and rare in the general population, i.e., associated with VTE (filter strategy 3). Together, all these strategies might increase the chances of finding the genetic risk factor for VTE present in family D and family K. Abbreviations: SNPs, single nucleotide variants/polymorphisms; INDELs, insertions and deletions; MAF, minor allele frequency; GoNL, Genome of the Netherlands project database, 498 unrelated Dutch individuals; EVS_EA, NHLBI Exome Sequencing Project database, 4,300 European-American unrelated individuals; 1000G, 1000 Genomes Project, 2,500 individuals from about 25 populations around the world; GIFT, Genetics In Familial Thrombosis study, 96 unrelated VTE cases with positive family history of VTE; MEGA, Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis study, up to 4,291 cases with VTE and 4,866 controls.](pone.0187699.g002){#pone.0187699.g002}

For filter strategy 1, we created a list of genes known or possibly associated with VTE based on the available literature. This list comprises a total of 126 genes and is available in [S1 File](#pone.0187699.s001){ref-type="supplementary-material"}. Following the selection of SNPs and INDELs located within these candidate genes, we enriched for variants more likely to affect protein function, by excluding non-coding variants without any potential splice site prediction or involving a low conserved base pair, as well as synonymous variants without any potential splice site prediction. Then, we tested the effect of these variants on hemostatic traits in cases from the GIFT study, although we realize that this approach is subject to collider bias \[[@pone.0187699.ref021],[@pone.0187699.ref022]\]. We analysed 413 cases, for which previously investigated hemostatic traits and genotypes were available from a previous genome-wide association study \[[@pone.0187699.ref014]\]. For more information on the association analysis see further below in this section.

For filter strategy 2, we identified all variants with minor allele frequency (MAF) equal or less than 5% in the NHLBI Exome Sequencing Project database, 4,300 European-American unrelated individuals (EVS_EA) \[[@pone.0187699.ref023]\] and 1000G database \[[@pone.0187699.ref024]\]. Then, we selected only variants identified in 5 or less (≤1%) individuals from GoNL, as these individuals share the same ethnic origin and geographic region as families D and K. To minimize genotyping errors, all intergenic variants and INDELs located exclusively in intronic regions were excluded from further analysis.

For filter strategy 3, we identified SNPs that were present in one or more GIFT cases for whom whole exome sequencing data was available, and with MAF equal or below than 5% in GoNL. We tested these SNPs for association with VTE by comparing the risk allele frequencies in GIFT (n = 96) with those present in GoNL (n = 498) or EVS_EA databases (n = 4,300). SNPs shared by members from both families were not considered in this filter strategy. Of note, SNPs available only in the GIFT database, i.e., only identified in cases with VTE, are retained for follow-up analysis in filter strategy 2.

After applying all the filter strategies, we evaluated each of the retained variants to minimize the presence of sequencing errors (e.g. those inherent to the technology used) \[[@pone.0187699.ref025],[@pone.0187699.ref026]\]. Variants located in duplicated genome regions, in homopolymeric regions or with MAF above 10% in 1000G or EVS_EA databases (resulting from filter strategy 3) were excluded from further analysis. Furthermore, when 2 or more SNPs were located in the same gene, we used SNiPA \[[@pone.0187699.ref027]\] to evaluate whether these SNPs were in high linkage disequilibrium (D\'\>0.9), and if so only one was taken for further analysis.

Finally, variants not present in dbSNP135 were classified as novel variants in this study. Yet, to facilitate the identification of all variants mentioned in this text, we have annotated these variants with a later version of dbSNP database, the dbSNP142.

Confirmation with Sanger sequencing or allele-specific PCR {#sec013}
----------------------------------------------------------

DNA samples available from affected and unaffected members from both families were used for validation and segregation analysis of the candidate variants. This was performed by standard bidirectional Sanger sequencing. We ranked the variants in terms of number of asymptomatic carriers within a family, and we used samples from the GENES and the MEGA studies for follow-up validation of the top ranked variants (i.e., those with the lowest number of asymptomatic carriers). In total, 6 variants were selected for follow-up validation: 2 variants from family D and 4 variants from family K. These variants were validated with Sanger sequencing or allele-specific PCR on DNA available from 36 samples from the GENES study and 9,157 samples from the MEGA study, respectively (primers available on request).

Statistical analysis {#sec014}
--------------------

### Testing for association between a SNP and VTE {#sec015}

For each SNP resulting from filter strategy 3, the allele frequencies between cases (GIFT) and controls (GoNL or EVS_EA) were compared using the Pearson's chi-square test with 1 degree of freedom. Associations with p\<0.05 were defined as putative associations. After applying Bonferroni correction, associations with p\<0.0003 (0.05/135) were considered to be statistically significant. SNPs located in the X chromosome were excluded from this analysis, since sex information from the individuals enrolled in GoNL was not available. Instead, we decided to select for further analysis all coding SNPs or novel non-coding SNPs located in the X chromosome, which were absent in GoNL database. The association between each SNP genotyped in MEGA and VTE was investigated using Fisher's exact test. The threshold for significance was set as p\< 0.05. The statistical analysis was performed using the software R (version 2.15.2).

### Association of SNPs from candidate genes on the variability of hemostatic traits {#sec016}

We performed linear regression analyses adjusted for age and sex to estimate the effect of each SNP resulted from filter strategy 1 on hemostatic traits known to associate with VTE. Investigated hemostatic traits were endogenous thrombin generation, plasma antigen or activity levels of fibrinogen, coagulation factors II, VII, VIII, IX, X, and XII, von Willebrand factor, antithrombin, protein C, protein S (total and free), protein Z, C4b binding protein, and anti-β2-glycoprotein I. The threshold for significance was set as p\< 0.05 and when we corrected for multiple testing, p\< 0.0004 was considered to be statistically significant. We repeated this analysis using some SNPs resulted from filter strategy 2 but solely for 3 hemostatic traits: fibrinogen, protein S total and protein S free levels. The statistical analysis was performed using the software SPSS (version 22).

Sample size considerations {#sec017}
--------------------------

Using standard power calculation methods for case-control studies, the MEGA study would be sufficient to detect relative risks of 4 for a dominant trait with a minor allele frequency of 0.1%, with a power of 80% and 5% two-sided type I-error\[[@pone.0187699.ref028]\].

Results {#sec018}
=======

Whole exome sequencing {#sec019}
----------------------

### Families {#sec020}

The sequencing yielded an average sequencing depth of \~53x per sample, with at least 86% of the targeted region covered more than 10x. Each individual had \~64,000 SNPs and \~12,000 INDELs, making in total 121,347 SNPs and 23,364 INDELs to undergo our filtering strategies ([Fig 2](#pone.0187699.g002){ref-type="fig"}).

### GIFT study {#sec021}

Sequence data was successfully generated for all 96 subjects. In the combined 96 samples, the average read depth was 63X and the median was 62X. This value ranged from 38X to 80X according to individuals. In 91 samples, the average is above 50X, in the remaining 5 samples, the average read depth was around 40X. For all samples, the coverage was over 10x at greater than 88% of the targeted region. The median \[range\] number of SNPs and INDELs with read depth above 10x detected per sample was 87,461 \[78,956--90,627\] and 2,768 \[2,249--2,997\], respectively.

Overall, 13,286 genes carried at least one new or rare (\<0.5%) coding variant (based on reported 1000g2012apr_eur frequency), and the average number of such variants per individual was 1,456.

Variants shared by all affected relatives {#sec022}
-----------------------------------------

We identified all single nucleotide polymorphisms and insertions and deletions shared by all affected relatives from the families D and K. Tables [1](#pone.0187699.t001){ref-type="table"} and [2](#pone.0187699.t002){ref-type="table"} list the variants identified in autosomes and X chromosome, respectively.

10.1371/journal.pone.0187699.t001

###### Number of variants located in autosomes retained after each filter step.

Abbreviations: SNPs, single nucleotide variants/polymorphisms; INDELs, insertions and deletions; MAF, minor allele frequency; GoNL, Genome of the Netherlands project database, 498 unrelated Dutch individuals; EA, NHLBI Exome Sequencing Project database, 4,300 European-American unrelated individuals; 1000G, 1000 Genomes Project, 2,500 individuals from about 25 populations around the world; VTE, venous thromboembolism; GIFT, Genetics In Familial Thrombosis study, 96 unrelated VTE cases with positive family history of VTE.

![](pone.0187699.t001){#pone.0187699.t001g}

                                                                       SNPs                                            INDELs                                    
  -------------------------------------------------------------------- ----------------------------------------------- -------- -------- ------- ------- ------- -------
  **1,2,3**                                                            1\. Present in all affected individuals         995      1467     21029   80      89      2073
  2\. Only heterozygous                                                276                                             733      207      22      40      101     
                                                                                                                                                                 
  **1**                                                                3\. Within candidate genes                      4        7        0       0       0       0
  4\. Retain only with functional effect                               2                                               3        0        0       0       0       
  **Selected for Sanger sequencing**                                   **2**                                           **3**    **0**    **0**   **0**   **0**   
                                                                                                                                                                 
  **2**                                                                3\. MAF_EA \< = 5%                              111      391      140     14      28      92
  4\. MAF_1000G \< = 5%                                                36                                              201      90       12      20      86      
  5\. Less than 6 carriers in GoNL (total of 498 unrelated controls)   10                                              56       10       12      20      83      
  6\. Exclude intergenic                                               10                                              54       2        10      20      69      
  7\. INDELs: Exclude intronic                                         10                                              54       2        3       3       4       
  **Selected for Sanger sequencing**                                   **10**                                          **48**   **0**    **2**   **2**   **1**   
                                                                                                                                                                 
  **3**                                                                3\. Present in GIFT (total of 96 index cases)   265      663      \-      \-      \-      \-
  4\. MAF_GoNL \< = 5%                                                 28                                              167      \-       \-      \-      \-      
  5\. Retain putative associations with VTE (p-value\< = 0.05)         6                                               13       \-       \-      \-      \-      
  6\. Remove if MAF in controls \> MAF in cases                        5                                               10       \-       \-      \-      \-      
  **Selected for Sanger sequencing**                                   **3**                                           **6**    **-**    **-**   **-**   **-**   
                                                                                                                                                                 
  **1,2,3**                                                            **Total variants for Sanger sequencing**        **14**   **53**   **0**   **2**   **2**   **1**

10.1371/journal.pone.0187699.t002

###### Number of variants located in the X chromosome retained after each filter step.

Abbreviations: SNPs, single nucleotide variants/polymorphisms; INDELs, insertions and deletions; MAF, minor allele frequency; GoNL, Genome of the Netherlands project database, 498 unrelated Dutch individuals; EA, NHLBI Exome Sequencing Project database, 4,300 European-American unrelated individuals; 1000G, 1000 Genomes Project, 2,500 individuals from about 25 populations around the world.

![](pone.0187699.t002){#pone.0187699.t002g}

                                                       SNPs                                       INDELs                                   
  ---------------------------------------------------- ------------------------------------------ -------- ------- ------- ------- ------- -------
  **1,2**                                              1\. Present in all affected individuals    8        30      339     0       0       45
  2\. Only heterozygous females and homozygous males   2                                          20       0       0       0       0       
                                                                                                                                           
  **1**                                                3\. Within candidate genes                 0        0       0       0       0       0
  4\. Retain only with functional effect               0                                          0        0       0       0       0       
  **Selected for Sanger sequencing**                   **0**                                      **0**    **0**   **0**   **0**   **0**   
                                                                                                                                           
  **2**                                                3\. MAF_EA \< = 5%                         1        15      0       0       0       0
  4\. MAF_1000G\< = 5%                                 0                                          6        0       0       0       0       
  5\. Less than 6 carriers in GoNL                     0                                          1        0       0       0       0       
  6\. Exclude intergenic                               0                                          1        0       0       0       0       
  7\. INDELs: Exclude intronic                         0                                          1        0       0       0       0       
  **Selected for Sanger sequencing**                   **0**                                      **1**    **0**   **0**   **0**   **0**   
                                                                                                                                           
  **1,2**                                              **Total variants for Sanger sequencing**   **0**    **1**   **0**   **0**   **0**   **0**

### Autosomal variants {#sec023}

We identified 276 SNPs and 22 INDELs exclusively shared by all affected individuals from family D, 733 SNPs and 40 INDELs exclusively shared by all affected individuals from family K, and 207 SNPs and 101 INDELs shared by all affected individuals from both families. All these variants were present in a heterozygous form. Only few SNPs were novel: 3 SNPs exclusive to family D, 36 SNPs exclusive to family K and 9 SNPs shared by both families.

### Variants located in the X chromosome {#sec024}

We identified 2 and 20 SNPs, but no INDELs, shared by all affected individuals from family D and family K, respectively. Only 1 SNP was novel. The 10 individuals with these 22 SNPs shared no SNPs.

Selection of the candidate variants {#sec025}
-----------------------------------

Tables [1](#pone.0187699.t001){ref-type="table"} and [2](#pone.0187699.t002){ref-type="table"} display the number of variants retained after each filtering step. Concerning the variants exclusive to family D, 2 SNPs, 10 SNPs and 3 INDELs, and 5 SNPs remained after applying all the filtering steps from the filter strategies 1, 2, and 3. One SNP, *MAP3K6* rs55841735, was common between 2 of the 3 filter strategies. Concerning the variants exclusive to family K, 3 SNPs, 55 SNPs and 3 INDELs, and 10 SNPs remained after applying all the filtering steps from the filter strategies 1, 2, and 3. Four SNPs, *LRPPRC* rs372371276, *SRBD1* rs34959371, *FSCN3* rs34941808, and *ZNF816* rs369724877 were common between 2 of the 3 filter strategies. Regarding the variants shared by all 10 affected individuals, no variants remained for analysis, except for filter strategy 2. Using this filter strategy, 2 SNPs and 4 INDELs remained for analysis. Of note, 1 of the variants that resulted from filter strategy 2 was identified only among cases of VTE (family K and GIFT). This was an intronic SNP in the *NEBL* gene (rs61849814).

After all the variants have been individually checked, we excluded 12 SNPs and 5 INDELs from further validation with Sanger sequencing. Five of these variants were intronic SNPs from family K, which we considered not relevant for further analysis (details can be found in [S2 File](#pone.0187699.s002){ref-type="supplementary-material"}).

The 73 candidate variants retained for validation (68 SNPs and 5 INDELs) are listed in the [Table 3](#pone.0187699.t003){ref-type="table"} along with the predicted impact on protein function, and MAF in various databases.

10.1371/journal.pone.0187699.t003

###### List of the 73 variants selected for validation.

Abbreviations: Chr, Chromosome; Ref, reference allele; Obs, observed allele; HOM, homozygous; HET, heterozygous; Func, variant function; SNPs, single nucleotide variants/polymorphisms; MAF, minor allele frequency; GoNL, Genome of the Netherlands project database, 498 unrelated Dutch individuals; EVS_EA, NHLBI Exome Sequencing Project database, 4,300 European-American unrelated individuals; 1000G, 1000 Genomes Project, 2,500 individuals from about 25 populations around the world; GIFT, Genetics In Familial Thrombosis study, 96 unrelated VTE cases with positive family history of VTE; GoNL, Genome of the Netherlands project database, 498 unrelated Dutch individuals.
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  Chr   Start       End         Ref   Obs   Func             Gene             Exonic Func               dbSNP135      MAF EA_6500\_%   MAF GIFT\_% (assuming_allCalled)   MAF 1000G 2012apr_ALL\_%   GoNL number of genotypes (HOM_Ref/HET/HOM_Obs)   Filter strategy
  ----- ----------- ----------- ----- ----- ---------------- ---------------- ------------------------- ------------- ---------------- ---------------------------------- -------------------------- ------------------------------------------------ -----------------
  1     1905479     1905479     C     T     exonic           *KIAA1751*       nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  1     6211042     6211042     C     G     intronic         *CHD5*                                                   0.05             0.00                               0                          NA                                               2
  1     27688743    27688743    T     C     splicing         *MAP3K6*                                   rs55841735    0.41             1.56                               0.41                       494/4/0                                          2.3
  1     117122285   117122285   \-    TCC   exonic           *IGSF3*          nonframeshift insertion                 NA               21.77                              0                          NA                                               2
  1     156354348   156354348   C     \-    splicing         *RHBG*                                     rs11303415    NA               0.00                               0                          NA                                               2
  1     231377078   231377078   C     A     UTR5             *GNPAT*                                                  0.01             0.00                               0                          493/1/0                                          2
  1     234536943   234536943   T     G     exonic           *TARBP1*         nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  2     43965641    43965641    T     C     exonic           *PLEKHH2*        synonymous SNP                          NA               0.52                               0                          NA                                               2
  2     44184604    44184604    T     C     intronic         *LRPPRC*                                                 0.02             0.52                               0                          NA                                               2.3
  2     45640302    45640302    G     C     exonic           *SRBD1*          nonsynonymous SNP         rs34959371    0.43             1.04                               0.27                       497/1/0                                          2.3
  2     207175476   207175476   G     T     exonic           *ZDBF2*          nonsynonymous SNP         rs36095066    0.87             0.00                               0.46                       493/5/0                                          2
  3     42251580    42251580    \-    GGA   exonic           *TRAK1*          nonframeshift insertion                 NA               0.00                               0                          NA                                               2
  3     107932728   107932728   G     A     intronic         *IFT57*                                                  0.40             0.52                               0.09                       496/2/0                                          2
  3     111667982   111667982   C     T     intronic         *PHLDB2*                                   rs116705395   NA               0.00                               0.18                       497/1/0                                          2
  3     121097497   121097497   C     T     intronic         *STXBP5L*                                  rs182808568   NA               0.00                               0.14                       494/4/0                                          2
  3     121260373   121260373   G     A     intronic         *POLQ*                                     rs183249693   0.08             0.00                               0.09                       494/4/0                                          2
  3     124829057   124829057   A     G     exonic           *SLC12A8*        synonymous SNP            rs11714448    3.09             6.25                               1                          470/28/0                                         3
  3     129308276   129308276   G     A     exonic           *PLXND1*         nonsynonymous SNP         rs146072632   0.21             0.00                               0                          481/1/0                                          2
  3     195510838   195510838   G     A     exonic           *MUC4*           nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  3     195591020   195591020   T     G     UTR3             *TNK2*                                     rs112362099   1.00             2.60                               1                          480/18/0                                         3
  4     144346515   144346515   C     G     intronic         *GAB1*                                     rs187533266   NA               0.00                               0.23                       497/1/0                                          2
  5     176305151   176305151   C     A     intronic         *UNC5A*                                                  0.01             0.00                               0                          NA                                               2
  5     180661310   180661310   G     T     exonic           *TRIM41*         synonymous SNP                          0.03             0.00                               0                          NA                                               2
  7     100016781   100016781   T     C     exonic           *ZCWPW1*         nonsynonymous SNP         rs141450215   0.50             0.00                               0.27                       496/2/0                                          2
  7     103061356   103061356   T     A     intronic         *SLC26A5*                                                NA               0.00                               0                          497/1/0                                          2
  7     110763503   110763503   A     G     exonic           *LRRN3*          synonymous SNP            rs35229264    0.47             0.00                               0.09                       495/3/0                                          2
  7     111936315   111936315   C     T     exonic           *ZNF277*         synonymous SNP            rs142208106   0.00             0.00                               0                          496/2/0                                          2
  7     127229265   127229265   C     T     intronic         *ARF5*                                                   0.56             1.56                               0.23                       487/4/0                                          2
  7     127239585   127239585   C     T     exonic           *FSCN3*          nonsynonymous SNP         rs34941808    0.60             1.56                               0.14                       495/3/0                                          2.3
  9     2039776     2039776     \-    CAG   exonic           *SMARCA2*        nonframeshift insertion                 NA               11.54                              0                          NA                                               2
  9     2648286     2648286     G     A     exonic           *VLDLR*          nonsynonymous SNP         rs35339834    0.13             0.00                               0.05                       497/1/0                                          2
  9     5919929     5919929     T     C     exonic           *KIAA2026*       nonsynonymous SNP                       0.07             0.00                               0                          NA                                               2
  9     8486132     8486132     G     C     exonic           *PTPRD*          synonymous SNP            rs144111555   0.10             0.00                               0.27                       496/2/0                                          2
  9     136917482   136917482   G     A     exonic           *BRD3*           synonymous SNP            rs61731642    0.00             0.00                               0.09                       NA                                               2
  9     140145895   140145895   C     G     ncRNA_intronic   *LOC100129722*                                           0.17             0.52                               0                          NA                                               2
  10    21318672    21318672    A     C     intronic         *NEBL*                                     rs61849814    NA               1.04                               0                          NA                                               2
  11    62601915    62601915    G     A     exonic           *WDR74*          nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  11    63883847    63883847    C     T     exonic           *FLRT1*          synonymous SNP                          NA               0.00                               0                          NA                                               2
  11    65293664    65293664    G     A     exonic           *SCYL1*          nonsynonymous SNP                       0.01             0.00                               0                          NA                                               2
  11    66472221    66472221    G     A     exonic           *SPTBN2*         synonymous SNP            rs144939155   0.25             0.52                               0.18                       479/3/0                                          2
  11    66638474    66638474    C     A     intronic         *PC*                                                     NA               0.00                               0                          NA                                               2
  11    68177405    68177405    C     T     exonic           *LRP5*           synonymous SNP            rs145456776   0.03             0.00                               0                          NA                                               2
  12    130919182   130919182   G     A     intronic         *RIMBP2*                                                 NA               0.00                               0                          NA                                               2
  12    131311749   131311749   A     C     exonic           *STX2*           nonsynonymous SNP         rs137928907   2.55             2.08                               1                          463/32/1                                         1
  12    133306808   133306808   C     T     exonic           *ANKLE2*         nonsynonymous SNP         rs149597645   1.63             3.65                               1                          477/21/0                                         3
  13    113824899   113824899   T     C     intronic         *PROZ*                                     rs3024787     NA               0.00                               0                          493/5/0                                          2
  14    105360291   105360291   C     G     intronic         *KIAA0284*                                 rs185909273   NA               0.00                               0.18                       496/2/0                                          2
  14    105418571   105418571   C     T     exonic           *AHNAK2*         nonsynonymous SNP                       0.00             0.00                               0                          NA                                               2
  16    602505      602505      C     T     exonic           *SOLH*           synonymous SNP                          0.00             0.00                               0                          NA                                               2
  16    4940366     4940366     A     G     intronic         *PPL*                                                    0.14             0.52                               0.18                       497/1/0                                          2
  16    5083391     5083391     C     G     exonic           *NAGPA*          nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  17    45360730    45360730    T     C     exonic           *ITGB3*          nonsynonymous SNP         rs5918        15.17            14.58                              9                          341/145/12                                       1
  17    64210757    64210757    C     A     exonic           *APOH*           nonsynonymous SNP         rs4581        23.76            21.88                              47                         311/166/21                                       1
  17    65713943    65713943    \-    A     upstream         *NOL11*                                                  NA               0.00                               0                          NA                                               2
  17    66274384    66274384    C     T     exonic           *SLC16A6*        synonymous SNP            rs149995088   0.29             0.52                               0.09                       494/4/0                                          2
  17    67310584    67310584    A     G     UTR5             *ABCA5*                                                  NA               0.00                               0                          NA                                               2
  17    72443156    72443156    G     A     exonic           *GPRC5C*         nonsynonymous SNP         rs142232982   0.05             0.00                               0.09                       NA                                               2
  17    72740355    72740355    G     A     intronic         *RAB37*                                                  NA               0.00                               0                          NA                                               2
  18    43496563    43496563    G     A     intronic         *EPG5*                                                   0.12             0.00                               0                          497/1/0                                          2
  19    15569378    15569378    G     C     exonic           *RASAL3*         nonsynonymous SNP         rs58123634    4.84             6.77                               3                          457/25/0                                         3
  19    47207685    47207685    G     C     intronic         *PRKD2*                                                  0.08             0.00                               0                          494/1/0                                          2
  19    49254538    49254538    T     G     exonic           *FUT1*           nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  19    49713534    49713534    G     A     exonic           *TRPM4*          nonsynonymous SNP                       NA               0.00                               0                          NA                                               2
  19    49878275    49878275    G     A     exonic           *DKKL1*          nonsynonymous SNP         rs35389403    0.33             0.00                               1                          NA                                               2
  19    49910139    49910139    C     G     intronic         *CCDC155*                                  rs112074780   0.39             0.00                               1                          NA                                               2
  19    50163098    50163098    G     A     intronic         *IRF3*                                                   NA               0.00                               0                          NA                                               2
  19    51503285    51503285    C     T     exonic           *KLK8*           nonsynonymous SNP         rs16988799    5.15             2.60                               5                          441/56/1                                         1
  19    51528041    51528041    C     T     exonic           *KLK11*          nonsynonymous SNP         rs3745539     7.53             7.29                               6                          421/71/5                                         1
  19    53454862    53454862    T     C     intronic         *ZNF816*                                                 0.08             0.52                               0                          497/1/0                                          2.3
  20    744270      744270      G     A     exonic           *SLC52A3*        synonymous SNP            rs139430185   0.05             0.00                               0                          497/1/0                                          2
  22    38890624    38890624    A     C     intronic         *DDX17*                                                  NA               0.00                               0                          497/1/0                                          2
  22    41736075    41736075    C     A     exonic           *ZC3H7B*         synonymous SNP                          NA               0.00                               0                          494/2/0                                          2
  X     117702143   117702143   C     G     intronic         *DOCK11*                                                 0.07                                                0                          NA                                               2

Validation of candidate variants {#sec026}
--------------------------------

We designed primers to validate the 73 candidate variants resulting from all filter strategies.

The presence of 5 variants, 4 SNPs (*IFT57* rs199895727, *IRF3* NM_001197122.1:c.1115-8C\>T, *MUC4* rs199718845 and *TRIM41* rs376725370) and 1 INDEL (*TRAK1* NM_001265609:c.1844_1845insGGA) could not be validated due to PCR problems. The presence of the remaining variants was evaluated by Sanger sequencing in affected and unaffected family members (including 1 additional affected member from family D for whom no whole exome sequencing data were available) ([S3 File](#pone.0187699.s003){ref-type="supplementary-material"}). We identified the variants with the lowest number of unaffected carriers based on the families' genotyping results. We selected 6 variants. These variants were located in 3 different loci: 2p21 (*PLEKHH2*, *LRPPRC* and *SRBD1*) and 5q35.2 (*UNC5A*) based on family K, and 17q25.1 (*GPRC5C* and *RAB37*) based on family D. Three of these variants, all from the 2p21 locus, were also present in the GIFT study. One individual carried the 3 variants and one individual carried the *SRBD1* variant only.

Variants genotyped in individuals from GENES and MEGA {#sec027}
-----------------------------------------------------

We examined the prevalence of the 6 rare candidate SNPs, *PLEKHH2* NM_172069:c.3105T\>C, *LRPPRC* rs372371276, *SRBD1* rs34959371, *UNC5A* NM_133369.2:c.1869+23C\>A, *GPRC5C* rs142232982 and, *RAB37* rs556450784, in 36 affected individuals from GENES and, 4,291 affected and 4,866 unaffected individuals from MEGA. We found additional carriers in MEGA, except for the *UNC5A* SNP. We initially found 2 carriers of the *PLEKHH2* variant (1 case and 1 control, and surprisingly, the case was homozygous for the minor allele) but after validation with Sanger sequencing, the case was found to be wild type. We also found 2 carriers of the *LRPPRC* variant (1 case and 1 control), 38 carriers of the *SRBD1* variant (14 cases and 24 controls), 19 carriers of the *GPRC5C* variant (7 cases and 12 controls), and 19 carriers of the *RAB37* variant (6 cases and 13 controls). Some individuals carried 2 of these disease candidate variants simultaneously: 1 control carried both *LRPPRC* and *SRBD1* variants, and 4 controls carried both *GPRC5C* and *RAB37* variants. We compared the distribution of the disease risk alleles between affected and unaffected individuals and found no statistically significant differences or clear signals of an association ([Table 4](#pone.0187699.t004){ref-type="table"}).

10.1371/journal.pone.0187699.t004

###### Candidate variants genotyped in MEGA.

![](pone.0187699.t004){#pone.0187699.t004g}

  Gene        Variant         Reference/alternate alleles   Number of MEGA cases   Number of MEGA controls   P-value   OR     95% CI                     
  ----------- --------------- ----------------------------- ---------------------- ------------------------- --------- ------ -------- --- ------ ------ -------------
  *PLEKHH2*   c.3105T\>C      T/C                           4031                   0                         0         4691   1        0   NA     NA     NA
  *LRPPRC*    rs372371276     A/G                           4044                   1                         0         4662   1        0   1      1.15   0.01--90.44
  *SRBD1*     rs34959371      G/C                           3829                   14                        0         4400   24       0   0.26   0.67   0.32--1.35
  *UNC5A*     c.1869+23C\>A   C/A                           3981                   0                         0         4613   0        0   NA     NA     NA
  *GPRC5C*    rs142232982     G/A                           4021                   7                         0         4637   12       0   0.49   0.67   0.22--1.86
  *RAB37*     rs556450784     G/A                           4036                   6                         0         4598   13       0   0.25   0.53   0.16--1.48

Association of SNPs from candidate genes with variability of hemostatic traits {#sec028}
------------------------------------------------------------------------------

We investigated whether any of the 5 candidate SNPs resulting from filter strategy 1 (*STX2* rs137928907, *ITGB3* rs5918, *APOH* rs4581, *KLK8* rs16988799, and *KLK11* rs3745539) were associated with one or more hemostatic traits known to associate with VTE. We investigated 413 individuals from GIFT, for whom both genotype and hemostatic traits data were available. No genotype was available or could be imputed for the *STX2* rs137928907. We found associations for the variants located in chromosome 17, *APOH* rs4581 and *ITGB3* rs5918. After correcting for multiple testing only one association remained significant. The *ITGB3* rs5918 remained associated with FX levels. All putative associations are shown in [Table 5](#pone.0187699.t005){ref-type="table"}.

10.1371/journal.pone.0187699.t005

###### Results of SNPs with P-values less than 0.05 for association with a haemostatic trait (samples from GIFT study).

Putative associations were found for 2 of the candidate SNPs resulting from filter strategy 1. No genotype data was available for the *STX2* rs137928907. Abbreviations: NA, not available; -, no association; Ref, reference allele; Alt, alternate allele; N, number; CI, confidence interval.

![](pone.0187699.t005){#pone.0187699.t005g}

  Gene variant                                         Lab outcome             N individuals by genotype   Mean \<lab outcome\> by genotype   Multiple regression analysis   Single regression analysis                                                                                             
  ---------------------------------------------------- ----------------------- --------------------------- ---------------------------------- ------------------------------ ---------------------------- --------------- -------------- --------------- ------------ --------------- ------------- -------
  ***STX2* rs137928907**                               *NA*                    *NA*                        *NA*                               *NA*                           *NA*                         *NA*            *NA*           *NA*            *NA*         *NA*            *NA*          *NA*
  ***ITGB3* rs5918**                                   Factor X levels         197                         70                                 4                              99 ± u/dL                    107 ± 23 u/dL   114 ± 3 u/dL   6.7             9 ± 2 u/dL   3 × 10^−4^      3.91--13.19   0.001
  Factor IX levels                                     197                     70                          4                                  101 ± u/dL                     106 ± u/dL                   106 ± u/dL      5.6            5 ± 2 u/dL      0.013        1.14--9.68      0.029         
  Protein S levels                                     197                     70                          4                                  93 ± u/dL                      98 ± u/dL                    101 ± u/dL      10.5           6 ± 2 u/dL      0.002        2.35--10.57     0.013         
  Protein S free levels                                197                     70                          4                                  88 ± u/dL                      97 ± u/dL                    88 ± u/dL       11.4           13 ± 3 u/dL     0.001        6.25--15.63     0.006         
  Thrombin generation lagtime (Tissue factor = 1pM)    197                     70                          4                                  8.7 ±.1 min                    9.7 ±.0 min                  8.4 ±.4 min     8.2            0.9 ± 0.4 min   0.029        0.09--1.71      0.062         
  ***APOH* rs4581**                                    Protein S free levels   182                         78                                 11                             88 ± u/dL                    91 ± u/dL       106 ± u/dL     8.3             3 ± 3 u/dL   0.108           0.00--9.38    0.035
  Factor V ag                                          274                     117                         19                                 112 ± u/dL                     104 ± u/dL                   98 ± u/dL       2.6            -7 ± 3 u/dL     0.027        -12.49---0.77   0.02          
  Factor V act                                         274                     116                         18                                 103 ± u/dL                     100 ± u/dL                   95 ± u/dL       2.3            -3 ± 2 u/dL     0.037        -0.66---0.21    0.032         
  Thrombin generation lagtime (Tissue factor = 1pM)    182                     78                          11                                 8.7 ±.0 min                    9.6 ±.0 min                  10.0 ±.6 min    8              0.7 ± 0.4 min   0.04         0.03--1.44      0.032         
  Thrombin generation lagtime (Tissue factor = 10pM)   182                     78                          11                                 1.9 ± 0.3 min                  2.0 ± 0.4 min                2.0 ± 0.2 min   4.6            0.1 ± 0.0 min   0.018        0.02--0.17      0.014         
  ***KLK8* rs16988799**                                \-                      \-                          \-                                 \-                             \-                           \-              \-             \-              \-           \-              \-            \-
  ***KLK11* rs3745539**                                \-                      \-                          \-                                 \-                             \-                           \-              \-             \-              \-           \-              \-            \-

We also investigated whether the 3 candidate variants that were identified from filter strategy 2, *RAB37* rs556450784, *GPRC5C* rs142232982 and *SRBD1* rs34959371, were associated with fibrinogen, total protein S and free protein S levels in MEGA ([S4 File](#pone.0187699.s004){ref-type="supplementary-material"}).

Discussion {#sec029}
==========

Our approach enabled us to narrow down the list of genetic variants to 3 candidate loci, but we were unable to identify the causative variant underlying the risk for disease in 2 families with unexplained familial VTE. Either variants in known hemostatic genes as well as rare variants across the exome are unlikely to explain the VTE tendency in these families.

A major strength of this study was the availability of families with multiple affected individuals that included cases with an early age of onset. Although family members are more likely to share environmental risk factors than unrelated individuals, young individuals without acquired causes for VTE are more likely to carry variants with large effect sizes \[[@pone.0187699.ref029]\]. Assuming that affected individuals from a family would all share the same susceptibility allele, we could reduce the list of candidate SNPs from 121,347 to 1,238, and candidate INDELs from 23,364 to 163 before applying more stringent filter strategies. It is worth mentioning that an analysis-by-exclusion approach with exomes from unaffected relatives could have reduced the number of shared variants to a minimum. We chose to only sequence exomes from affected relatives because an analysis-by-exclusion also has its limitations in VTE family studies, as we could have missed disease risk variants because unaffected individuals from the same family can still develop the disease at older age.

Our choice to pursue a high-throughput exome sequencing approach enabled us to identify both rare and common coding variants. Moreover, this approach allowed us to focus not only on variants located in genes previously reported to be associated with VTE, but also in novel genes.

Many patients and families included in gene identification studies still remain without a molecular diagnosis \[[@pone.0187699.ref030]\]. One of the main reasons is because ranking variants is often a challenge in these studies \[[@pone.0187699.ref031]\]. We reported our results from applying three different filter strategies, as reporting the results from different approaches is essential to improve variant ranking strategies. One common approach consists of prioritizing non-synonymous variants located in or near genes known to be associated with the disease of interest or a related phenotype. These variants are much more likely to be involved in the disease than variants elsewhere in the genome. This is the foundation of our filter strategy 1. Another approach consists of prioritizing rare and low frequency variants. Rare and low frequency variants are often at the basis of inherited risk for VTE, like in the case of deficiencies in one of the natural anticoagulants and the factor V Leiden and prothrombin mutations \[[@pone.0187699.ref030]\]. The use of rare and low frequency variants is the foundation of the remaining two filter strategies. Compared with the filter strategy 2, the filter strategy 3 has a more relaxed MAF threshold since we cannot exclude that young controls included in our study might develop VTE associated with inherited thrombophilia at a later time. Data from a set of cases with family history of VTE (GIFT) was key to rank these variants although we cannot ignore the possibility of generating false negative results due to the small sample size (only 96 unrelated cases). Of note, since there is growing evidence that supports a functional role for synonymous rare codons \[[@pone.0187699.ref032],[@pone.0187699.ref033]\], we retained synonymous variants for analysis in both filter strategies 2 and 3.

Several genome-wide studies, and more recently also whole exome sequencing studies have been conducted to identify genetic risk factors for VTE \[[@pone.0187699.ref009]--[@pone.0187699.ref014],[@pone.0187699.ref034]--[@pone.0187699.ref036]\]. However, nearly all variants that have been robustly found to be associated with the risk for this disease are located within known susceptibility genes. In our study, the candidate variants resulting from filter strategy 1 are the least likely disease-causing variants, as there were a high number of unaffected carriers, including homozygotes. Furthermore, because the affected individuals from these families do not share abnormalities in hemostatic traits known to affect the risk of VTE, variants with a large effect size are unlikely to be present among the known VTE susceptibility genes.

All variants tested for segregation with the disease showed incomplete penetrance, i.e. unaffected individuals carrying the putative pathogenic variant were found among the families. Yet, an autosomal dominant incomplete penetrance is likely. Despite the inheritance pattern being consistent with an autosomal dominant mode for both families, family K oldest generation (proband's parents) did not experience VTE. Furthermore, given the different clinical manifestations of VTE within the affected individuals, it is plausible that other factors, such as environmental or other genetic modifiers, are also involved in the pathogenesis of the disease in these families. Although some studies suggest that the proportion of the variance attributable to shared familial environment factors is small \[[@pone.0187699.ref037],[@pone.0187699.ref038]\], it is difficult to predict the likelihood of finding VTE-causing variants based solely on the severity of the disease within a single family.

With regard to the 6 variants genotyped in MEGA, we found additional carriers among cases and controls, except for the UNC5A variant, for which no carrier was found. The 2 putative pathogenic variants identified for family D, the *GPRC5C* and *RAB37* SNPs, were found to be more prevalent in the Netherlands than in the worldwide population. This was unexpected because none of these variants was present in GoNL database. An explanation could be that these genomic regions were not covered in GoNL database. With regard to the 4 putative pathogenic variants identified in family K, the rarity of the variants identified in *UNC5A*, *LRPPRC* and *PLEKHH2* genes suggests that these variants are deleterious. However, whether these variants predispose to VTE remains unknown. The *UNC5A* variant seems to be a family-specific variant, as we have not identified additional carriers nor it is reported in any of the available database. The *PLEKHH2* variant was found in 1 unaffected individual while the *LRPPRC* variant was found 1 affected and 1 unaffected individual, both with negative family history for VTE. Noteworthy that despite being so rare, both *LRPPRC* and *PLEKHH2* variants were found in 1 affected individual with positive family history for VTE in GIFT. Co-segregation with the phenotype in other affected family members may shed further light on the causality of this locus. This is particularly important because these variants are predicted to have no functional consequence and biological evidence might be difficult to address.

According to the GWAS catalog database, variants in *SRBD1*, *LRPPRC* and *RAB37* genes have been reported to be associated with other phenotypes: *SRBD1* rs3213787 has been associated with normal tension glaucoma\[[@pone.0187699.ref039]\], *LRPPRC* rs13387221 has been associated with cognitive ability (intelligence) in childhood\[[@pone.0187699.ref040]\] and *RAB37* rs10512597 has been associated with fibrinogen levels\[[@pone.0187699.ref041],[@pone.0187699.ref042]\]. This last association is intriguing because elevated total fibrinogen levels and reduced fibrinogen gamma′ levels are associated with increased risk for VTE\[[@pone.0187699.ref043]\]. Common SNPs at the locus 17q25.1, which includes the *RAB37* rs10512597-C, have been associated with reduced fibrinogen and C-reactive protein levels\[[@pone.0187699.ref041],[@pone.0187699.ref042]\], which suggests that regulators of fibrinogen and C-reactive protein levels might be present at this locus. However, in the GIFT study, the *RAB37* rs10512597-C was not associated with fibrinogen levels (β = 0.07, 95% CI = -0.05--0.20, p = 0.251) but instead, it was associated with protein S levels (β = 4.37, 95% CI = 1.00--7.74, p = 0.011) but not free protein S levels (β = 0.010, 95% CI = -0.006--0.026, p = 0. 236) (MLRC, PHR, unpublished observation August 2015). Both candidate variants from family D, *RAB37* rs556450784 and *GPRC5C* rs142232982, were not associated with fibrinogen or protein S levels in MEGA.

Variants located within the nearest upstream or the nearest downstream genes of the following candidate genes, *PLEKHH2*, *LRPPRC*, and *SRBD2*, all located in the 2p21 locus, have also been reported as associated with various phenotypes according to the GWAS catalog database. Variants in *THADA* have been associated with age-related hearing impairment\[[@pone.0187699.ref044]\], Crohn\'s disease\[[@pone.0187699.ref045]\], DNA methylation variation\[[@pone.0187699.ref046]\], hair morphology\[[@pone.0187699.ref047]\], inflammatory bowel disease\[[@pone.0187699.ref048]\], mitochondrial DNA levels\[[@pone.0187699.ref049]\], orofacial clefts\[[@pone.0187699.ref050],[@pone.0187699.ref051]\], platelet counts\[[@pone.0187699.ref052]\], polycystic ovary syndrome\[[@pone.0187699.ref053],[@pone.0187699.ref054]\], prostate cancer\[[@pone.0187699.ref055]\], response to amphetamines\[[@pone.0187699.ref056]\], and type 2 diabetes\[[@pone.0187699.ref057]\]. Variants in *ABCG8* have been associated with LDL cholesterol\[[@pone.0187699.ref058]--[@pone.0187699.ref063]\], total cholesterol\[[@pone.0187699.ref058]--[@pone.0187699.ref060]\], campesterol levels\[[@pone.0187699.ref064]\], and gallstones\[[@pone.0187699.ref065]\]. Finally, variants in *PRKCE* have been associated with various red blood cell traits (red blood cell counts\[[@pone.0187699.ref066]\], hematocrit\[[@pone.0187699.ref066]--[@pone.0187699.ref069]\], and hemoglobin\[[@pone.0187699.ref066],[@pone.0187699.ref067]\]), as well as pulmonary function decline\[[@pone.0187699.ref070]\], QT interval\[[@pone.0187699.ref071]\], metabolite levels (X-11787)\[[@pone.0187699.ref072]\], and suicide risk\[[@pone.0187699.ref072]\]. While some of these phenotypes might be linked with the risk of developing VTE, the association of the 2p21 locus with VTE risk has not been reported before.

Our study has some limitations. First, although different types of genetic variation exist, we have investigated only SNPs and INDELs. Second, we had to employ different filtering strategies to select only potentially clinically relevant variants, as the number of variants shared by the affected family members was very high. We cannot exclude the possibility of missing the causative variant after applying these strategies. Nevertheless, because there are no established filtering strategies for identification of VTE causing genes, we have validated with Sanger sequencing additional variants that were not retained after applying the different filter strategies (details in [S2 File](#pone.0187699.s002){ref-type="supplementary-material"}). Yet, none of these additional variants is likely to explain the increased risk for VTE in families D and K. As a side note, researchers can reutilize these data and apply filter strategies other than the ones described in our manuscript to identify putative disease-causing variants (the information about all variants shared by the relatives can be found in [S2 File](#pone.0187699.s002){ref-type="supplementary-material"}). For example, researchers can prioritize the variants based on other candidate genes \[[@pone.0187699.ref073]\] or on scores that estimate the variant effect \[[@pone.0187699.ref074]\] and compare these with their relevant datasets. Third, given that all 10 samples from the 2 families have undergone the same experimental protocol and bioinformatics analysis, systematic errors are likely to be present in this dataset. Some of these errors might lead to erroneous variant calls. To minimize this type of errors, for each variant identified in our analysis, we have obtained the genotype information for all samples. This allowed us to distinguish samples with homozygous reference calls from samples with no genotype calls. We used this information and selected only SNPs for which the genotype information was available in all 10 individuals. Therefore, although discerning rare variants from sequencing errors remains a big challenge in next generation sequencing data analysis, we think that rare variants exclusively shared by one family are less likely to be sequencing errors in our study. Yet, we cannot exclude the possibility of incomplete coverage of some genes, a limitation inherent to the next generation sequencing technique. Fourth, although all variants analyzed are based on families D and K results, the GIFT, EVS_EA and GoNL data were generated with different library preparation, sequencing and bioinformatics methodology. Cross-dataset comparisons (comparing GIFT cases with EVS_EA or GoNL) are in general prone to technical bias. Fifth, our sample size in MEGA was powered to detect genotype relative risks greater than 4 at the significance level of 0.05 for risk allele frequencies greater than 0.10%, and the power to detect a relative risk of 1.5 was low. Sixth, although our results argue that coding variants in known genes or rare coding variants across the exome are unlikely to explain the VTE tendency in these families, these results are not generalizable to other families with unexplained VTE. Finally, our whole exome sequencing data was generated by the end of 2011 and a significant improvement on sequencing technology and data analysis has been made over the last years. The feasibility of whole exome sequencing for identifying new VTE genetic variants is only as good as the quality of the data, so it could be that better coverage might lead to identification of more potential variants of interest.

In conclusion, despite extensive investigation, we did not find a definitive genetic cause for the increased risk of VTE in the 2 evaluated families. Our study suggests that rare variants within 3 candidate loci, 2p21, 5q35.2 and 17q25.1, have an impact on the risk of VTE in these families, but we could not find any evidence for the 6 rare variants genotyped in a large case-control association study.
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